VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
Nabtesco Corporation vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Nabtesco Corporation
6268 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Nabtesco Corporation's moat claims, evidence, and risks.
View 6268 analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: Nabtesco Corporation leads (91 / 100 vs 71 / 100 for AstraZeneca PLC).
- Segment focus: Nabtesco Corporation has 4 segments (34.2% in Component Solutions Business); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Quasi-Monopoly vs Oligopoly. Pricing power: Strong vs Strong.
- Moat breadth: Nabtesco Corporation has 5 moat types across 3 domains; AstraZeneca PLC has 4 across 3.
Primary market context
Nabtesco Corporation
Component Solutions Business
Precision reduction gears (RV reducers) for industrial robot joints
Global
Industrial robot manufacturers (OEMs)
Precision motion-control component supplier
34.2%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
Nabtesco Corporation strengths
AstraZeneca PLC strengths
Segment mix
Nabtesco Corporation segments
Full profile >Component Solutions Business
Quasi-Monopoly
Transport Solutions Business
Oligopoly
Accessibility Solutions Business
Quasi-Monopoly
Other Businesses
Quasi-Monopoly
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.